Advertisement
Advertisement

JANX

JANX logo

Janux Therapeutics, Inc. Common Stock

15.78
USD
Sponsored
-0.36
-2.23%
Jul 14, 15:59 UTC -4
Closed
exchange

After-Market

15.78

0.00
-0.03%

JANX Earnings Reports

Positive Surprise Ratio

JANX beat 14 of 20 last estimates.

70%

Next Report

Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$13.28M
/
-$0.43
Implied change from Q1 26 (Revenue/ EPS)
+255.80%
/
+10.26%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-21.82%

Janux Therapeutics, Inc. Common Stock earnings per share and revenue

On May 07, 2026, JANX reported earnings of -0.39 USD per share (EPS) for Q1 26, beating the estimate of -0.53 USD, resulting in a 27.36% surprise. Revenue reached 3.73 million, compared to an expected 3.91 million, with a -4.53% difference. The market reacted with a -2.51% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 15 analysts forecast an EPS of -0.43 USD, with revenue projected to reach 13.28 million USD, implying an increase of 10.26% EPS, and increase of 255.80% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
FAQ
For Q1 2026, Janux Therapeutics, Inc. Common Stock reported EPS of -$0.39, beating estimates by 27.36%, and revenue of $3.73M, -4.53% below expectations.
The stock price moved down -2.51%, changed from $14.54 before the earnings release to $14.18 the day after.
The next earning report is scheduled for Aug 11, 2026.
Based on 15 analysts, Janux Therapeutics, Inc. Common Stock is expected to report EPS of -$0.43 and revenue of $13.28M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement